Low-dose etanercept therapy in moderate to severe psoriasis in Korean

Journal of Dermatology

Volumn 35, Issue 8, 2008, Pages 484-490

  Na, Jung Im ^b   Kim, Jun Hyung ^b   Park, Kyoung Chan ^b   Youn, Sang Woong ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b NONE

Author keywords

Biologics; Etanercept; Psoriasis; Tumor necrosis factor

Indexed keywords

COLECALCIFEROL; CYCLOSPORIN; ETANERCEPT; RETINOID; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DEMYELINATING DISEASE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HEADACHE; HERPES ZOSTER; HUMAN; INJECTION SITE ERYTHEMA; LOW DRUG DOSE; MALE; PHOTOTHERAPY; POSTPRIMARY TUBERCULOSIS; PSORIASIS; PSORIASIS AREA SEVERITY INDEX 50; PSORIASIS SEVERITY INDEX; RETROSPECTIVE STUDY; SCORING SYSTEM; SOUTH KOREA; ULTRAVIOLET B RADIATION; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 49349107977     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2008.00508.x     Document Type: Article

References (31)

1. Goldsmith DR, Wagstaff AJ. Etanercept: a review of its use in the management of plaque psoriasis and psoriatic arthritis. Am J Clin Dermatol 2005 6 : 121 136.
2. Nickoloff BJ, Stevens SR. What have we learned in dermatology from the biologic therapies? J Am Acad Dermatol 2006 54 : S143 S151.
3. Culy CR, Keating GM. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs 2002 62 : 2493 2537.
4. Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 2004 363 : 675 681.
5. Lovell DJ, Giannini EH, Reiff A et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000 342 : 763 769.
6. Davis JC Jr., van der Heijde D, Braun J et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003 48 : 3230 3236.
7. Lew W, Lee E, Krueger JG. Psoriasis genomics: analysis of proinflammatory (type 1) gene expression in large plaque (Western) and small plaque (Asian) psoriasis vulgaris. Br J Dermatol 2004 150 : 668 676.
8. Gottlieb AB, Matheson RT, Lowe N et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003 139 : 1627 1632.
9. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003 349 : 2014 2022.
10. Papp KA, Tyring S, Lahfa M et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005 152 : 1304 1312.
11. Gordon K, Korman N, Frankel E et al. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol 2006 54 : S101 S111.
12. Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 2006 54 : S67 S80.
13. Papp KA. The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res 2006 298 : 7 15.
14. Gaspari A, Gottlieb AB, Kang S, Gordon K, Feng A, Zitnik RG. Enbrel improves the clinical and pathologic features of psoriasis. J Invest Dermatol 2002 119 : 236.
15. Feldman SR, Kimball AB, Krueger GG, Woolley JM, Lalla D, Jahreis A. Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol 2005 53 : 887 889.
16. Tyring S, Gottlieb A, Papp K et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial. Lancet 2006 367 : 29 35.
17. Tyring S, Gordon KB, Poulin Y et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007 143 : 719 726.
18. Gottlieb AB, Gordon K, Wang A, Zitnik R. Withdrawal from etanercept after successful clinical response in psoriasis patients: disease characteristics and the durability of treatment response. J Am Acad Dermatol 2004 50 : S146.
19. Feldman SR. Intermittent dosing of biologics for psoriasis. J Dermatolog Treat 2006 17 : 5.
20. Leonardi CL, Elewski B, Camisa C, Zitnik R. The efficacy and safety of etanercept in the re-treatment of psoriasis after relapse. J Am Acad Dermatol 2004 50 : S146.
21. Moore A, Gordon KB, Kang S et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007 56 : 598 603.
22. Krueger GG, Elewski B, Papp K, Wang A, Zitnik R, Jahreis A. Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial. J Am Acad Dermatol 2006 54 : S112 S119.
23. van de Kerkhof PC. Consistent control of psoriasis by continuous long-term therapy: the promise of biological treatments. J Eur Acad Dermatol Venereol 2006 20 : 639 650.
24. Youn JI, Kim BS. A clinical study on psoriasis. Kor J Dermatol 1996 34 : 886 892.
25. Immunex Corp. Enbrel (etanercept) prescribing information. [Cited 30 May 2007.] Available from URL: http://www.enbrel.com/prescribing-information.jsp.
26. European Medicines Agency. Enbrel (etanercept) summary of product characteristics. [Cited 30 May 2007.] Available from URL: AB, Leonardi CL, Goffe BS et al. Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database. J Am Acad Dermatol 2006 54 : S92 S100.
27. Mohan AK, Cote TR, Block JA, Manadan AM, Siegel JN, Braun MM. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004 39 : 295 299.
28. Centocor Inc. Remicade(infliximab) package insert. [Cited 28 June 2007.] Available from URL: http://www.remicade.com/pdf/PPI.pdf
29. Abbott lab. Humira(adalimumab) package insert. [Cited 28 June 2007.] Available from URL: http://www.rxabbott.com/pdf/humira.pdf
30. Yang JW, Jeon MJ, Kim SJ et al. Usefulness of tuberculin skin test by tuberculin PPD RT23 2 TU. Tuberc Respir Dis 2002 53 : 401 408.
31. Joung CI, Kang TY, Lee HS et al. Tuberculosis incidence with Infliximab in Korean patients with chronic autoimmune diseases-predictive value of tuberculin test and chest radiograph and effectiveness of tuberculosis prophylaxis regimen. Korean J Med 2003 26 : S289.